Part the Cloud's 2026 funding supports early Phase 1 and Phase 2/2a human trials of new Alzheimer's and dementia therapies. Part the Cloud is the Alzheimer's Association's funding program for high-risk, high-reward treatment ideas moving from the laboratory toward larger late-stage trials.
The program made two awards in 2026. The Alzheimer's Association said in the January funding announcement that it committed more than $11 million, building on more than $90 million across 83 earlier studies. It then added nearly $7 million in September, bringing its cumulative total to 88 trials worldwide, according to the September investment update.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the 2026 money pays for
- Which treatment ideas get priority
- One example now in people: an oral anti-inflammation drug
- How these trials fit the wider 2026 pipeline
- What patients and caregivers can do now
What the 2026 money pays for
The 2026 grants fund proof-of-concept trials in people, not basic laboratory work alone. These are small early studies that test safety, dosing, and early signs of biological effect. Results decide whether a drug deserves a larger, longer trial.
This role is deliberately catalytic. The Alzheimer's Association reports recipients have later raised more than $3 billion in federal, venture, and other follow-on funding. Early support opens the door, but later funding carries the drug forward.
Which treatment ideas get priority
The 2026 programs favor diverse mechanisms rather than one single approach. Priority areas in the Alzheimer's Association 2026 requests include combination trials using at least two drug approaches. They also include gene-targeting Phase 1 and Phase 2 trials aimed at genetic drivers of dementia.
A third priority is molecules first found with artificial intelligence. That funding helps move an AI-discovered candidate toward first-in-human testing. Together, the three tracks widen the range of ideas reaching people.
One example now in people: an oral anti-inflammation drug
One recipient is NeuroTherapia's NTRX-07, a first-in-class oral drug aimed at neuroinflammation. Neuroinflammation is harmful immune activity in the brain linked to Alzheimer's damage. Part the Cloud funded its Phase IIa study in Alzheimer's patients.
The study enrolled 48 adults with mild cognitive impairment or mild-to-moderate Alzheimer's. Sites were in Hungary, Poland, and the Czech Republic, Tech Times reported in its trial report. Participants received 90 mg taken by mouth each day or placebo for 28 days.
How these trials fit the wider 2026 pipeline
Part the Cloud trials are a small early slice of a much larger field. The Jan. 1, 2026 pipeline analysis by Cummings and colleagues counted 192 trials testing 158 drugs, as detailed in the peer-reviewed pipeline paper.
That total included 54 Phase 3, 89 Phase 2, and 49 Phase 1 trials. That count was up from 182 trials and 138 drugs in 2025. Growth came across phases, with many candidates still in early testing. Most experimental drugs never reach approval, so breadth matters.
What patients and caregivers can do now
This funding does not mean immediate access to new treatments. Early-phase results show whether further study is justified, not whether a drug works.
Families should view 2026 recipients as investigational options. Practical steps help: Bring a caregiver to that visit to track answers and next steps.
- Write down diagnosis, stage, medicines, and genetic test results if available.
- Ask the treating physician which recruiting trials match that profile.
- Ask about phase, placebo chance, visit burden, travel, costs, and how participation affects current care.
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: Accuracy, Limits, and Evidence Gaps for Adults With New Memory Symptoms
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: Questions Family Caregivers Can Ask About the Research
- The NIA 2026 Dementia Care and Caregiving Summit Report: Care-Planning Implications for Family Caregivers
